Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences Names Merdad Parsey Chief Medical Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2019 | 09:09am EST

By Colin Kellaher

Gilead Sciences on Monday said it named Merdad Parsey chief medical officer, effective Nov. 1.

The Foster City, Calif., biopharmaceutical company said Mr. Parsey is joining from Roche Holdings AG's (ROG.EB) Genentech Inc. unit, where he serves as senior vice president of early clinical development in the research and early development group.

Gilead in July said John McHutchison was stepping down as chief scientific officer and head of research and development. Mr. McHutchison was later named president and chief executive of clinical-stage biotechnology company Assembly Biosciences.

Gilead said Mr. Parsey, who will be responsible for the company's global clinical development and medical affairs organizations, will report directly to Chairman and Chief Executive Daniel O'Day under a new leadership structure, as will William Lee, who serves as executive vice president of research.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ASSEMBLY BIOSCIENCES, INC. -2.21% 14.16 Delayed Quote.-35.99%
GILEAD SCIENCES -0.50% 64.32 Delayed Quote.3.34%
ROCHE HOLDING AG 0.05% 298.1 Delayed Quote.22.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
11/11GILEAD SCIENCES : New Data on Filgotinib in Rheumatoid Arthritis Demonstrate Dur..
AQ
11/11GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
AQ
11/11GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
AQ
11/11GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
AQ
11/08GILEAD SCIENCES : Did You Invest in Gilead Sciences?
BU
11/08GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
BU
11/08GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
BU
11/08GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
BU
11/07GILEAD SCIENCES : United States sues Gilead for patent violation on HIV preventi..
AQ
11/07Health Care Up After Teva, Cardinal Health Reports -- Health Care Roundup
DJ
More news
Financials (USD)
Sales 2019 22 300 M
EBIT 2019 11 501 M
Net income 2019 4 320 M
Finance 2019 3 105 M
Yield 2019 3,84%
P/E ratio 2019 18,2x
P/E ratio 2020 11,3x
EV / Sales2019 3,57x
EV / Sales2020 3,52x
Capitalization 82 753 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 78,33  $
Last Close Price 65,41  $
Spread / Highest target 45,2%
Spread / Average Target 19,8%
Spread / Lowest Target -8,27%
EPS Revisions
Managers
NameTitle
Daniel O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES3.34%82 753
VERTEX PHARMACEUTICALS21.84%50 394
REGENERON PHARMACEUTICALS-7.82%35 474
WUXI APPTEC CO., LTD.73.35%21 914
GENMAB40.33%14 081
BEIGENE, LTD.36.69%11 493